Christine Ann Miller
President and CEO
Bio:
Christine Ann Miller is a forward-thinking, transformational leader who has dedicated her career to establishing clinical, operational, and commercial excellence across the pharmaceutical lifecycle. From the potential of a promising molecule to successful market launch and equitable access for all, she builds strategies and teams that are fit for the purpose of helping people live better lives.
In her current role as President and CEO of Melinta Therapeutics, a company owned by Deerfield Management, Christine is accelerating its transformation, redefining the portfolio from pure play antibiotics to become a leader in the acute care space. She has defined 4 strategic priorities to navigate the company through the transition to a new vision, mission, strategy, and culture. Under Christine’s leadership, the company is executing on a strategic plan focused on building a profitable and sustainable business model that has resulted in profitability with a 60%+ revenue growth, 94% employee engagement, and revenue and EBITDA performance surpassing 2022 targets.
During her time at Melinta, the portfolio expanded with two product approvals. Approved in 2021, KIMYRSA™ (oritavancin). After securing exclusive commercialization rights in the U.S. for rezafungin from Cidara Therapeutics, REZZAYO™ (rezafungin for injection) was approved by the FDA in 2023 – making it first new drug in the therapeutic area in more than 10 years.